

Catalog # 10-3743


Tafamidis

CAS# 594839-88-0

PF-06291826

2-(3,5-Dichlorophenyl)-6-benzoxazolecarboxylic acid

Lot # X102240



A potent and selective transthyretin (TTR) kinetic stabilizer. It binds selectively and with negative cooperativity to the two normally unoccupied thyroxine binding sites of the TTR tetramer ($K_d = \sim 2$ and ~ 200 nM)¹. Stabilizes wild-type and mutant TTR under varying conditions *in vitro* ($EC_{50} = 2.7$ - 3.2 μ M).¹ Clinically useful for the treatment of familial amyloid polyneuropathy^{2,3} and TTR-related cardiomyopathy⁴.

- 1) Bulawa *et al.* (2012), *Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits amyloid cascade*; Proc. Natl. Acad. Sci. USA, **109** 9629
- 2) Scott (2014), *Tafamidis: a review of its use in familial amyloid polyneuropathy*; Drugs, **74** 1371
- 3) Zhao *et al.* (2019), *Tafamidis, a Noninvasive Therapy for Delaying Transthyretin Familial Amyloid Polyneuropathy: Systemic Review and Meta-analysis*; J. Clin. Neurol., **15** 108
- 4) Lorenzini and Elliott (2019), *Tafamidis for the treatment of transthyretin amyloidosis*; Future Cardiol., **15** 53

PHYSICAL DATA

Molecular Weight:	308.12
Molecular Formula:	C ₁₄ H ₇ Cl ₂ NO ₃
Purity:	98% by TLC
	NMR: (Conforms)
Solubility:	DMSO (up to 20 mg/ml)
Physical Description:	Off-white solid
Storage and Stability:	Store as supplied desiccated at -20°C for up to 2 years from the date of purchase. Solutions in DMSO may be stored at -20°C for up to 3 months.

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications.